First Trust NYSE Arca Biotechnology Index Fund (FBT)

NYSEARCA: FBT · IEX Real-Time Price · USD
128.60
-2.46 (-1.88%)
Sep 26, 2022 4:00 PM EDT - Market closed
-1.88%
Assets $1.27B
NAV $131.11
Expense Ratio 0.55%
PE Ratio 15.11
Shares Out 9.70M
Dividend (ttm) $2.21
Dividend Yield 1.72%
Ex-Dividend Date Dec 30, 2021
1-Year Return -25.63%
Volume 27,360
Open 130.44
Previous Close 131.06
Day's Range 128.51 - 131.95
52-Week Low 121.68
52-Week High 172.92
Beta 0.85
Holdings 31
Inception Date Jun 19, 2006

About FBT

The fund will normally invest at least 90% of its net assets (including investment borrowings) in the common stocks and depositary receipts that comprise the index. The index is an equal-dollar weighted index designed to measure the performance of a cross section of small, mid and large capitalization companies in the biotechnology industry that are primarily involved in the use of biological processes to develop products or provide services.

Asset Class Equity
Sector Biotech
Region Global
Issuer First Trust Portfolios
Stock Exchange NYSEARCA
Ticker Symbol FBT
Index Tracked NYSE Arca Biotechnology Index

Top 10 Holdings

40.61% of assets
Name Symbol Weight
Alnylam Pharmaceuticals ALNY 4.91%
Agios Pharmaceuticals AGIO 4.62%
Sarepta Therapeutics SRPT 4.61%
Regeneron Pharmaceuticals REGN 4.08%
Ionis Pharmaceuticals IONS 3.91%
ACADIA Pharmaceuticals ACAD 3.90%
Neurocrine Biosciences NBIX 3.87%
Illumina ILMN 3.58%
Gilead Sciences GILD 3.57%
FibroGen FGEN 3.55%
View More Holdings

Dividends

Ex-Dividend Amount Pay Date
Dec 30, 2021 $2.2136 Jan 10, 2022
Sep 23, 2015 $0.0197 Sep 30, 2015
Jun 24, 2015 $0.0649 Jun 30, 2015
Mar 25, 2015 $0.0476 Mar 31, 2015
Dec 23, 2014 $0.0524 Dec 31, 2014
Full Dividend History

News

Should You Invest in the First Trust NYSE Arca Biotechnology ETF (FBT)?

Sector ETF report for FBT

1 week ago - Zacks Investment Research

Is First Trust NYSE Arca Biotechnology ETF (FBT) a Strong ETF Right Now?

Smart Beta ETF report for FBT

2 weeks ago - Zacks Investment Research

Biotech ETFs That Outperformed Last Week

Biotech ETFs was the biggest gainer last week.

9 months ago - Zacks Investment Research

Healthcare Emerges as Best Sector of Last Week: 5 Top ETFs

Wall Street was downbeat last week with all indexes in the red. Still, Healthcare sector emerged as a key winner last week.

Other symbols: BBPGERMPBESBIO
9 months ago - Zacks Investment Research

Can Biotech ETFs Gain From Positive Booster Update?

In an effort to combat the coronavirus outbreak and accelerate the distribution process of extra doses in the United States, the FDA has approved the vaccine booster shots.

Other symbols: BBHBTECIBBXBI
11 months ago - Zacks Investment Research

Biotech ETFs to Benefit From Latest Booster Update

The U.S. government's plans to make COVID-19 vaccine booster shots available from next month will likely increase the profits of vaccine makers.

Other symbols: BBHBTECIBBXBI
1 year ago - Zacks Investment Research

Delta Variant Surge Brings Biotech ETFs in Focus

The biotech sector seems like a lucrative investment space as the delta variant of coronavirus continues to spread.

Other symbols: BBHBTECIBBXBI
1 year ago - Zacks Investment Research

Top-Performing Biotech ETFs of Last Week

Investors may want to tap the bullishness in the sector with the best biotech ETFs of last week.

1 year ago - Zacks Investment Research

Will Biotech ETFs Benefit from Biogen's New Alzheimer's Drug?

Biotech investors may have reason to celebrate this week, as the FDA approved Biogen's Alzheimer's disease drug Aducanumab on Monday, ushering in the first medication to be allowed by U.S. regulators to...

Other symbols: BBHPBE
1 year ago - ETF Trends

5 Top ETFs With Exposure To Biogen

For the first time in 18 years, there was a new treatment for Alzheimer's Disease approved by the FDA. Aducanumab from Biogen Inc (NASDAQ: BIIB) was approved as a drug that can reduce the clinical decli...

Other symbols: BIIBBBHIBBPBEPKW
1 year ago - Benzinga

Biotech ETFs to Suffer as US Backs IP Waiver for COVID-19 Vaccines

The Biden administration recently informed about supporting the waiver of intellectual property protections for COVID-19 vaccines that has been proposed by South Africa and India.

Other symbols: BBHBTECIBBXBI
1 year ago - Zacks Investment Research

Top COVID-19 Vaccine Stories of April Put Biotech ETFs in Focus

Let's take a look at some top coronavirus vaccine stories of April and the possible impact they can have on biotech ETFs.

1 year ago - Zacks Investment Research

Top COVID-19 Vaccine Stories of March Put Biotech ETFs in Focus

Investors are closely tracking the progress in coronavirus vaccine development amid the pandemic's renewed resurgence with multiple mutants.

Other symbols: BBHBTECIBBXBI
1 year ago - Zacks Investment Research

A Guide to Biotech ETF Investing Amid the Coronavirus Crisis

The biotech space had an impressive run on the bourses in 2020 as the coronavirus pandemic triggered a race to roll out vaccine and treatment.

1 year ago - Zacks Investment Research

ETF Market Outlook & Picks for 2021

Two ETF experts share their market outlook and top picks for 2021.

1 year ago - Zacks Investment Research

ETFs to Tap AstraZeneca Mega-Deal to Buy Alexion

AstraZeneca has agreed to buy rare-disease specialist Alexion Pharmaceuticals for $39 billion. The deal would represent the biggest transaction in pharmaceuticals since 2019.

Other symbols: BBHPBEPJPPPH
1 year ago - Zacks Investment Research

3 ETFs For AstraZeneca's $39B Alexion Pharmaceuticals Takeover

The biotechnology space is always fertile territory for mergers and acquisitions, and that theme was on display over the weekend when AstraZeneca (NYSE: AZN) announced a $39-billion takeover of Alexion ...

Other symbols: BBHPBE
1 year ago - Benzinga

ETF Sectors to Bet on Positive Vaccine News

The introduction of the coronavirus vaccine is expected to help in the economic recovery, especially for sectors which have taken a hit from the social-distancing and lockdown measures.

1 year ago - Zacks Investment Research

Can't Get Enough Biotech Exposure in Your Portfolio?

As coronavirus cases start to tick upwards once more, the race to create a vaccine will only intensify, boding well for the biotechnology sector. ETF investors may want to keep an eye on biotech funds, ...

Other symbols: ARKGBBHXBI
1 year ago - ETF Trends

Biotech ETFs at multi-week highs, extending winning streak

Biotechnology exchange-traded funds outperformed Tuesday as investors focused on next-generation solutions to the coronavirus and more. The ARK Genomic Revolution ETF was up 2.2% in the early afternoon,...

Other symbols: BBHIBBXBI
1 year ago - Market Watch

Biotech ETFs at two-week highs on upbeat vaccine news

Biotech exchange-traded funds got a bounce Friday from bullish news on coronavirus treatments. The ALPS Medical Breakthroughs ETF , the ARK Genomic Revolution ETF , and the First Trust NYSE Arca Biotech...

Other symbols: ARKGSBIO
1 year ago - Market Watch

7 Biotech Stocks To Buy For Profit From The Vaccine Crunch

As the race to develop a vaccine continues, these biotech stocks could be high risk, high return propositions. The post 7 Biotech Stocks To Buy For Profit From The Vaccine Crunch appeared first on Inves...

Other symbols: GILDGERMPFEREGNWST
1 year ago - InvestorPlace

Biotech ETFs in Focus as the COVID-19 Vaccine Race Intensifies

Johnson & Johnson's entry into the late-stage trials has increased optimism in the coronavirus vaccine development.

Other symbols: ARKGBBHIBBXBI
1 year ago - Zacks Investment Research

3 Healthcare ETFs to Buy for Health and Safety

Not all healthcare ETFs are the same and as this group of three proves, that can be a positive for savvy investors. The post 3 Healthcare ETFs to Buy for Health and Safety appeared first on InvestorPlace.

Other symbols: EDOCTDOC
2 years ago - InvestorPlace

Encouraging Election Year History for this Biotech ETF

Healthcare is one of the most politically sensitive sectors and that sensitivity is on full display in recent weeks with biotechnology ETFs, including the First Trust NYSE Arca Biotechnology Index Fund ...

2 years ago - ETF Trends